Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis

KA Papp, L Guenther, B Boyden, FG Larsen, RJ Harvima, JJ Guilhou, R Kaufmann, S Rogers, PCM van de Kerkhof, LI Hanssen, Eva Tegner, G Burg, D Talbot, A Chu

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

169 Citeringar (SciVal)

Sammanfattning

Background: Calcipotriene and betamethasone dipropionate are topical treatments for psoriasis vulgaris. Their mode of action is different. Improved risk/benefit may result with concomitant use of the two compounds together. A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product. Objective. We compared the clinical efficacy of a fixed combination of calcipotriene and betamethasone clipropionate in a new vehicle to calcipotriene in the new vehicle, betamethasone in the new vehicle, and the new vehicle alone. Methods: This was an international, multicenter, prospective, randomized, double-blind, parallel-group, 4-week study in patients with psoriasis vulgaris amenable to topical treatment. Results. The mean percentage reduction in PASI from baseline to end of treatment was 73.2% in the combination group (n = 301), 48.8% in the calcipotriene group (n = 308), 63.1% in the betamethasone dipropionate group (n = 312) and 28.8% in the new vehicle group (n = 107), (P < .001). The mean percentage reduction in PASI during the first week was 48.1%, 28.4%, 41.4%, and 21.5%, respectively (P < .001). Conclusion: A combination product of calcipotriene 50 mug/g and betamethasone dipropionate 0.5 mg/g in the new vehicle shows superior efficacy with a more rapid onset of action than the new vehicle containing either constituent alone in the treatment of psoriasis vulgaris.
Originalspråkengelska
Sidor (från-till)48-54
TidskriftJournal of American Academy of Dermatology
Volym48
Utgåva1
DOI
StatusPublished - 2003

Ämnesklassifikation (UKÄ)

  • Dermatologi och venereologi

Fingeravtryck

Utforska forskningsämnen för ”Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här